Akebia Therapeutics Share Price Today
(NASDAQ: AKBA)

Name: Akebia Therapeutics Share Price Today (NASDAQ: AKBA) - Akebia Therapeutics Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Akebia Therapeutics share price is $2.4 & ₹205.10 as on 26 Apr 2025, 2.30 'hrs' IST

$2.4

▲

0.12

(5.26%)

Live

View live Akebia Therapeutics share price in Dollar and Rupees. Guide to invest in Akebia Therapeutics stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Akebia Therapeutics, along with analyst recommendations, forecasts, and comprehensive financials.

Akebia Therapeutics share price movements

Today's Low: $2.26
Today's High: $2.40
$2.40
5.83%
Downside
Day's Volatility :5.83%
Upside
0.0%
52 Weeks Low: $0.80
52 Weeks High: $2.89
$2.40
66.67%
Downside
52 Weeks Volatility :72.32%
Upside
16.96%

Akebia Therapeutics (AKBA) Returns

Period	Akebia Therapeutics Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	-4.2%	-4.8%	0.0%
6 Months	43.4%	-7.5%	0.0%
1 Year	71.43%	-1.8%	0.0%
3 Years	410.64%	2.1%	-9.5%

Akebia Therapeutics (AKBA) Key Statistics

in dollars & INR

Previous Close	$2.28
Open	$2.26
Today's High	$2.4
Today's Low	$2.26
Market Capitalization	$564.3M
Today's Volume	$2.3M
52 Week High	$2.89
52 Week Low	$0.8
Revenue TTM	$160.2M
EBITDA	$-8.7M
Earnings Per Share (EPS)	$-0.33
Profit Margin	-43.33%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-553.45%

How to invest in Akebia Therapeutics Stock (AKBA) from India?

It is very easy for Indian residents to invest directly in Akebia Therapeutics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Akebia Therapeutics stock in both Indian Rupees (INR) and US Dollars (USD). Search for Akebia Therapeutics or AKBA on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Akebia Therapeutics or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Akebia Therapeutics shares which would translate to 0.356 fractional shares of Akebia Therapeutics as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Akebia Therapeutics, in just a few clicks!

Returns in Akebia Therapeutics (AKBA) for Indian investors in Rupees

The Akebia Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Akebia Therapeutics investment value today

Current value as on today

₹1,83,026

Returns

₹83,026

(+83.03%)

Returns from Akebia Therapeutics Stock

₹80,451 (+80.45%)

Dollar Returns

₹2,575 (+2.58%)

Indian investors sentiment towards Akebia Therapeutics (AKBA)

-79%

Period: Mar 25, 2025 to Apr 24, 2025. Change in 30 Days versus previous period

Search interest for Akebia Therapeutics Stock from India on INDmoney has decreased by -79% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Akebia Therapeutics

BlackRock Inc
6.39%
Vanguard Group Inc
4.61%
State Street Corp
2.67%
SATTER MANAGEMENT CO., L.P.
2.43%
Geode Capital Management, LLC
2.03%
Renaissance Technologies Corp
1.62%

Analyst Recommendation on Akebia Therapeutics

Rating

Trend

Buy

88%Buy

11%Hold

0%Sell

Based on 9 Wall street analysts offering stock ratings for Akebia Therapeutics(by analysts ranked 0 to 5 stars)

Analyst Forecast on Akebia Therapeutics Stock (AKBA)

What analysts predicted

Upside of 207.29%

Target:

$7.38

Current:

$2.40

Insights on Akebia Therapeutics Stock (Ticker Symbol: AKBA)

Price Movement
In the last 1 month, AKBA stock has moved up by 16.9%
Increasing Revenue
Revenue is up for the last 2 quarters, 37.42M → 46.49M (in $), with an average increase of 19.5% per quarter
Decreasing Net Profit
Netprofit is down for the last 3 quarters, -8.58M → -22.80M (in $), with an average decrease of 73.7% per quarter

Akebia Therapeutics Technicals Summary

Sell

Neutral

Buy

Akebia Therapeutics is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Akebia Therapeutics (AKBA) Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Akebia Therapeutics Inc	18.75%	43.4%	71.43%	410.64%	-70.92%
Haleon Plc Spon Ads	2.59%	4.67%	22.74%	39.14%	39.14%
United Therapeutics Corporation	-4.63%	-14.98%	25.63%	69.57%	66.7%
Zoetis Inc.	-6.46%	-15.39%	-0.69%	-13.94%	19.53%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Akebia Therapeutics Inc	NA	NA	0.0	-0.15	-5.53	-0.12	NA	-0.22
Haleon Plc Spon Ads	24.36	24.36	1.84	0.41	0.09	0.05	0.02	1.79
United Therapeutics Corporation	12.03	12.03	1.43	27.29	0.19	0.12	NA	143.74
Zoetis Inc.	27.89	27.89	2.69	6.09	0.51	0.15	0.01	10.64

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Akebia Therapeutics Inc	Buy	$564.3M	-70.92%	NA	-43.33%
Haleon Plc Spon Ads	Buy	$46.1B	39.14%	24.36	12.84%
United Therapeutics Corporation	Buy	$13.3B	66.7%	12.03	41.53%
Zoetis Inc.	Buy	$67.9B	19.53%	27.89	26.86%

About Akebia Therapeutics

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD. The company is also developing AKB-9090 for treating cardiac surgery-related acute kidney injury and acute respiratory distress syndrome; and AKB-10108 for the treatment of retinopathy of prematurity in neonates. The company has license and collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of Vafseo in Japan and other Asian countries. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Organization	Akebia Therapeutics
Employees	181
CEO	Mr. John P. Butler MBA
Industry	Health Technology

Management People of Akebia Therapeutics

Name	Title
Mr. John P. Butler MBA	CEO, President & Director
Dr. Steven Keith Burke M.D.	Senior VP of Research & Development and Chief Medical Officer
Mr. Erik John Ostrowski M.B.A.	Senior VP, CFO & Chief Business Officer
Mr. Richard C. Malabre	Chief Accounting Officer
Ms. Kimberly Garko	Senior VP & Chief Technical Officer
Ms. Tracey Vetterick	Vice President of Portfolio Strategy & Corporate Administration
Mercedes Carrasco	Senior Director of Investor & Corporate Communications
Ms. Carolyn Rucci	Senior VP of Legal, General Counsel & Secretary
Ms. Meredith Bowman	Senior VP & Chief People Officer
Mr. Nicholas Grund	Senior VP & Chief Commercial Officer

Important FAQs about investing in AKBA Stock from India :

What is Akebia Therapeutics share price today?

Akebia Therapeutics share price today stands at $2.40, Open: $2.16 ; Previous Close: $2.28 ; High: $2.40 ; Low: $2.26 ; 52 Week High: $2.89 ; 52 Week Low: $0.80.

The stock opens at $2.16, after a previous close of $2.28. The stock reached a daily high of $2.40 and a low of $2.26, with a 52-week high of $2.89 and a 52-week low of $0.80.

Can Indians buy Akebia Therapeutics shares?

Yes, Indians can invest in the Akebia Therapeutics (AKBA) from India.

With INDmoney, you can buy Akebia Therapeutics at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Akebia Therapeutics at zero transaction cost.

How can I buy Akebia Therapeutics shares from India?

It is very easy to buy Akebia Therapeutics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Akebia Therapeutics (AKBA) be purchased?

Yes, you can buy fractional shares of Akebia Therapeutics with INDmoney app.

What are the documents required to start investing in Akebia Therapeutics stocks?

To start investing in Akebia Therapeutics, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.